Wedbush Reaffirms “Outperform” Rating for SpringWorks Therapeutics (NASDAQ:SWTX)

SpringWorks Therapeutics (NASDAQ:SWTX)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research report issued on Thursday,RTT News reports. They presently have a $81.00 price objective on the stock. Wedbush’s price objective suggests a potential upside of 35.16% from the company’s current price. Wedbush also issued estimates for SpringWorks Therapeutics’ Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at $0.23 EPS, FY2027 earnings at $3.55 EPS and FY2028 earnings at $8.09 EPS.

Several other research analysts also recently weighed in on the company. Guggenheim reduced their target price on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday, February 12th. Finally, Evercore ISI upped their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, SpringWorks Therapeutics has a consensus rating of “Buy” and a consensus target price of $71.50.

SpringWorks Therapeutics Stock Performance

SpringWorks Therapeutics stock traded up $4.20 during trading hours on Thursday, hitting $59.93. The company had a trading volume of 5,140,295 shares, compared to its average volume of 2,724,109. SpringWorks Therapeutics has a 1 year low of $28.21 and a 1 year high of $62.00. The firm has a market cap of $4.46 billion, a P/E ratio of -15.45 and a beta of 0.81. The company has a 50-day moving average price of $40.27 and a two-hundred day moving average price of $37.31.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. As a group, equities research analysts anticipate that SpringWorks Therapeutics will post -3.04 EPS for the current year.

Insider Activity at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total transaction of $839,400.00. Following the completion of the sale, the chief operating officer now directly owns 209,600 shares of the company’s stock, valued at $8,796,912. The trade was a 8.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Saqib Islam sold 48,000 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00. Following the transaction, the chief executive officer now directly owns 1,002,502 shares of the company’s stock, valued at approximately $53,433,356.60. This represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 313,822 shares of company stock valued at $16,802,876 over the last 90 days. 7.61% of the stock is owned by corporate insiders.

Institutional Trading of SpringWorks Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SWTX. Huntington National Bank grew its holdings in shares of SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after buying an additional 192 shares during the last quarter. AlphaQuest LLC increased its position in SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after purchasing an additional 414 shares during the last quarter. State of Wyoming boosted its holdings in SpringWorks Therapeutics by 39.5% in the fourth quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after acquiring an additional 433 shares during the last quarter. Barclays PLC grew its position in SpringWorks Therapeutics by 0.3% during the fourth quarter. Barclays PLC now owns 156,123 shares of the company’s stock valued at $5,641,000 after acquiring an additional 447 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock valued at $87,000 after acquiring an additional 474 shares during the period.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.